Dr. Patrick J. Hogan III, D.O.
Neurology (Neurology Physician)
5006 Center St Ste U
Tacoma, WA 98409
Who else practices at this address →
Pierce County includes primary care (20% of residents) and dental (11% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 54
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 158
Licensed in Washington since 1978, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
WA license OP00000793 (first issued 1978; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- South Puget Sound Neurology, PLLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 158
- Services billed
- 150,375
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 103,824 | 106 |
| Injection, incobotulinumtoxin a, 1 unit | 23,900 | 22 |
| Injection, abobotulinumtoxina, 5 units | 15,700 | 18 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 401 | 118 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 390 | 125 |
| Injection of chemical for paralysis of nerve muscles on side of face | 232 | 73 |
| Established patient office or other outpatient visit, 10-19 minutes | 72 | 51 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 67 | 25 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 37 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 36 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 67 payments worth $1,530 in total to this clinician.
| AbbVie Inc. | $777 |
|---|---|
| Teva Pharmaceuticals USA, Inc. | $290 |
| Pfizer Inc. | $125 |
| Ipsen Biopharmaceuticals, Inc | $72.71 |
| Revance Therapeutics, Inc. | $62.37 |
| Tonix Medicines, Inc. | $56.20 |
| UCB, Inc. | $43.15 |
| Lundbeck LLC | $29.88 |
| Food and Beverage | $1,451 |
|---|---|
| Education | $78.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Mar 12, 2025 | Education in-kind | $78.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 2 companies. The companies reported $83,137 in research payments for these studies, mostly to the institutions running them.
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
AbbVie Inc. - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06625060 - A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
AbbVie Inc. · Completed · NCT06218251 - A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
AbbVie Inc. · Completed · NCT04686136
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.